Company research
Parabilis Medicines, Inc.
CIK 1657677Updated Sep 24, 2026
SecurityPBLS · NASDAQ · equity
Name history
FOG PHARMACEUTICALS, INC. · through Dec 2, 2022
PBLS price & chart
Loading TradingView…
NASDAQ:PBLS on TradingView ↗About the company
We are a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. We leverage our proprietary platform to pioneer a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines.
In the news
Recent filings
Regulation FD Disclosure
Items 7.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
SCHEDULE 13G filing
10-Q filing
Show 5 more recent filings
Offerings
Registration 333-296032
- Gross proceeds
- 670000000.0
- Net proceeds
- 623100000.0
- Deal price
- 20.0
- Shares
- 33500000
- Offering price
- $20.00
- Ticker
- PBLS
Filing attachments
ck0001657677-ex99_1.htm · 8-K · 2026-08-25
EX-99.1 2 ck0001657677-ex99_1.htm EX-99.1 EX-99.1 Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors CAMBRIDGE, Mass., August 25, 2026 - Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the appointment of Craig L. Tendler, M.D., to its Board of Directors. Dr.…
Read attachment ↗ck0001657677-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 ck0001657677-ex99_1.htm EX-99.1 EX-99.1 Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company's proprietary HeliconTM platform; received $125M in upfront consid…
Read attachment ↗ck0001657677-ex99_2.htm · 8-K · 2026-08-13
EX-99.2 3 ck0001657677-ex99_2.htm EX-99.2 Creating Extraordinary Medicines Drugging Previously Undruggable Intracellular Drivers of Serious Diseases August 2026 Forward-looking statements & disclaimer PARABILIS MEDICINES This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "in…
Read attachment ↗ck0001657677-ex4_2.htm · S-1 · 2026-05-19
EX-4.2 4 ck0001657677-ex4_2.htm EX-4.2 EX-4.2 Exhibit 4.2 SIXTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS SIXTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 6th day of January, 2026, by and among Parabilis Medicines, Inc. (formerly known as “FOG Pharmaceuticals, Inc.”), a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and any Addi…
Read attachment ↗ck0001657677-ex4_3.htm · S-1 · 2026-05-19
EX-4.3 5 ck0001657677-ex4_3.htm EX-4.3 EX-4.3 Exhibit 4.3 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 6.3 AND 6.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE…
Read attachment ↗ck0001657677-ex4_4.htm · S-1 · 2026-05-19
EX-4.4 6 ck0001657677-ex4_4.htm EX-4.4 EX-4.4 Exhibit 4.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THIS INSTRUMENT AND ANY SECURITIES ISSUABLE PURSUANT HERETO HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOL…
Read attachment ↗